Literature DB >> 12407149

Population-based assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites.

Seppo Tuomaala1, Sebastian Eskelin, Ahti Tarkkanen, Tero Kivelä.   

Abstract

PURPOSE: To identify the clinical determinants of prognosis and the incidence of malignant conjunctival melanoma in whites.
METHODS: A nationwide search identified 85 patients in whom primary conjunctival melanoma was diagnosed in Finland between 1967 and 2000, all of whom were enrolled. Data were collected from the Finnish Cancer and Population Registries and from patients' charts in all involved hospitals. The age-specific and age-adjusted incidences were calculated. Clinical characteristics of the tumors were recorded and time to local recurrence and melanoma-specific survival were analyzed by Kaplan-Meier analysis and univariate and multivariate extended Cox regression.
RESULTS: The annual crude incidence of conjunctival melanoma in Finland was 0.51 per million inhabitants, and the age-adjusted incidence (mean, 0.54) increased from 0.4 to 0.8 during the 34-year study period. The median age at diagnosis was 60 years (range, 20-90). Clinically detectable primary acquired melanosis preceded or accompanied the primary tumor in 61% of patients. The 5-year cumulative proportion of cases with local recurrence was 0.36 (95% confidence interval [CI], 0.25-0.48). The melanoma-specific 5-and 10-year mortalities were 0.20 (95% CI, 0.12-0.32) and 0.38 (95% CI, 0.26-0.53), respectively. By multiple-event Cox regression, nonlimbal location of the primary tumor predicted a short time to local recurrence (hazard ratio [HR] 1.81, P = 0.024). Nonlimbal location of the primary tumor (HR 4.08, P = 0.023) and increasing tumor thickness (HR 1.19 for each millimeter change, P=0.063) were associated with increased mortality. Local recurrence, analyzed as a time-dependent covariate, also increased mortality (HR 1.39 for each recurrence, P = 0.014).
CONCLUSIONS: The incidence of conjunctival melanoma in the white population of Finland increased analogous to cutaneous melanoma. Nonlimbal tumors recur more often and are associated with decreased survival, independent of their greater thickness. Local recurrence contributes to mortality, whereas primary acquired melanosis was not associated with either outcome.

Entities:  

Mesh:

Year:  2002        PMID: 12407149

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  38 in total

Review 1.  Updates in Ocular Surface Tumor Diagnostics.

Authors:  Afshan A Nanji; Carolina Mercado; Anat Galor; Sander Dubovy; Carol L Karp
Journal:  Int Ophthalmol Clin       Date:  2017

2.  Management of conjunctival malignant melanoma: a review and update.

Authors:  James R Wong; Afshan A Nanji; Anat Galor; Carol L Karp
Journal:  Expert Rev Ophthalmol       Date:  2014-06

3.  Increased expression of hypoxia-inducible factor-1 alpha and its impact on transcriptional changes and prognosis in malignant tumours of the ocular adnexa.

Authors:  Clemens Alexander Klaus Lange; Patrick Lehnert; Stefaniya Konstantinova Boneva; Peipei Zhang; Franziska Ludwig; Martin Boeker; Klaus Hoffmeier; Ralf Horres; Günther Schlunck; Thomas Reinhard; Daniel Böhringer; Claudia Auw-Haedrich
Journal:  Eye (Lond)       Date:  2018-07-31       Impact factor: 3.775

Review 4.  Advances in the management of conjunctival melanoma.

Authors:  Gargi K Vora; Hakan Demirci; Brian Marr; Prithvi Mruthyunjaya
Journal:  Surv Ophthalmol       Date:  2016-06-16       Impact factor: 6.048

5.  Population-based incidence of conjunctival tumours in Olmsted County, Minnesota.

Authors:  Lauren A Dalvin; Diva R Salomão; Sanjay V Patel
Journal:  Br J Ophthalmol       Date:  2018-03-06       Impact factor: 4.638

6.  Conjunctival melanoma: association of cyclooxygenase-2 tumor expression to prognosis.

Authors:  Rita Pinto-Proença; Mariana Santos; Cristina Fonseca; Júlia Fernandes; Maria Filomena Gaspar; Rui Proença
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-01-02       Impact factor: 3.117

7.  Expression of matrix metalloproteinase (MMP)-2, MMP-9, and tissue inhibitor of MMP (TIMP)-1 in conjunctival melanomas and clinical implications.

Authors:  Hyoung Kyun Kim; Seoung Wan Chae; Kyung In Woo; Yoon-Duck Kim
Journal:  Jpn J Ophthalmol       Date:  2010-06-25       Impact factor: 2.447

8.  Conjunctival Melanoma during Pregnancy.

Authors:  Rana'a T Al-Jamal; Hardeep Singh Mudhar; Zanna Currie; Ian G Rennie; Sachin M Salvi
Journal:  Ocul Oncol Pathol       Date:  2016-11-08

Review 9.  Prognostication in eye cancer: the latest tumor, node, metastasis classification and beyond.

Authors:  T Kivelä; E Kujala
Journal:  Eye (Lond)       Date:  2012-12-21       Impact factor: 3.775

10.  Tumour-associated lymphangiogenesis in conjunctival malignant melanoma.

Authors:  P Zimmermann; T Dietrich; F Bock; F K Horn; C Hofmann-Rummelt; F E Kruse; C Cursiefen
Journal:  Br J Ophthalmol       Date:  2009-07-23       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.